GSK's lung cancer drug granted orphan status by FDA
10th Dec 2025 07:18
(Sharecast News) - GSK's risvutatug rezetecan has received Orphan Drug Designation from US regulators for the treatment of small-cell lung cancer, the UK pharma group announced on Wednesday.
Read moreBerenberg raises target price on GSK
25th Nov 2025 09:22
(Sharecast News) - Analysts at Berenberg slightly raised their target price on drugmaker GSK from £16 to £16.60 per share on Tuesday after it hosted chief financial officer Julie Brown for the eighth session of its annual pharma CFO series.
Read moreGSK files suit against AnaptysBio over licensing rights
21st Nov 2025 07:02
(Sharecast News) - GSK has filed a lawsuit against AnaptysBio in the US over licensing rights for its Jemperli cancer treatment.
Read moreGSK posts better-than-expected Q3, upgrades guidance
29th Oct 2025 07:20
(Sharecast News) - GSK raised its full-year guidance on Wednesday, after delivering stronger-than-expected third-quarter results, driven by robust growth in specialty medicines and steady contributions from its vaccines and general medicines divisions.
Read moreGSK lung cancer treatment gets EU orphan drug status
28th Oct 2025 07:14
(Sharecast News) - GSK on Tuesday said its treatment for small-cell lung cancer (SCLC) had received orphan drug status from the European Medicines Agency.
Read moreGSK shares lift on prostate cancer deal
27th Oct 2025 09:33
(Sharecast News) - GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.
Read moreGSK's Blenrep receives US FDA approval
24th Oct 2025 07:03
(Sharecast News) - Drugmaker GSK said on Friday that the US Food and Drug Administration had approved its Blenrep asset in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma.
Read moreGSK advances low-carbon inhaler, halts latozinemab study after mixed data
22nd Oct 2025 08:12
(Sharecast News) - Drugmaker GSK released two sets of trial data on Wednesday, covering its low-carbon asthma inhaler and a potential new treatment for multiple sclerosis.
Read moreGSK reports positive trial data for oral cUTI treatment, secures EU backing for simplified shingles vaccine
21st Oct 2025 07:13
(Sharecast News) - Drugmaker GSK made two key updates on Monday, with positive phase III trial results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, and a favourable regulatory opinion for a new prefilled syringe format of its shingles vaccine, Shingrix.
Read moreGSK shingles vaccine approved for expanded use in China
14th Oct 2025 07:07
(Sharecast News) - Pharma giant GSK has received regulatory approval in China to expand the use of its Shingrix shingles vaccine, the company announced on Tuesday.
Read moreLondon midday: UK stocks keep grinding towards year's highs
3rd Oct 2025 11:15
(Sharecast News) - Stocks are moving higher still shortly before midday with investor sentiment buoyed by fresh bullish news around the artificial intelligence space, even as investors keep a wary eye on the ongoing budget standoff in Washington D.C..
Read moreEmma Walmsley to step down as chief executive of GSK
29th Sep 2025 07:01
(Sharecast News) - Chief executive Emma Walmsley is to leave GSK, it was announced on Monday, after nearly a decade in the role.
Read moreTrump to impose tariffs of 100% on branded drug imports
26th Sep 2025 07:53
(Sharecast News) - Donald Trump is to impose tariffs of 100% on imports of pharmaceutical goods, it emerged on Friday, the latest salvo in the US president's global trade war.
Read moreGSK plans $30bn US investment as pharma faces tariff threat
17th Sep 2025 07:03
(Sharecast News) - GSK has announced plans to invest $30bn across the US in research and development and supply chain infrastructure over the next five years, amid fears of tariffs being imposed on the pharma industry by US President Donald Trump, who is in the UK on a state visit.
Read moreGSK gepotidacin edges closer to landmark approval for gonorrhoea
11th Aug 2025 07:15
(Sharecast News) - Drugmaker GSK moved closer to expanding its antibiotic portfolio on Monday, after US regulators accepted its application to review gepotidacin as a potential oral treatment for gonorrhoea.
Read more